Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study. - Ørbo HS; de Matos Kasahara T; Wolf AS; Bjørlykke KH; Sexton J; Jyssum I; Tveter AT; Solum G; Kjønstad IF; Bhandari S; Christensen IE; Kvien TK; et al. (The Lancet regional health. Europe, 2024)